<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096091</url>
  </required_header>
  <id_info>
    <org_study_id>InVITE 01</org_study_id>
    <nct_id>NCT05096091</nct_id>
  </id_info>
  <brief_title>International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)</brief_title>
  <acronym>InVITE</acronym>
  <official_title>International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Health Research and Development, Ministry of Health Republic of Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Partnership for Research on Ebola Virus in Liberia (PREVAIL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Clinical Research Center, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Medical Sciences and Nutrition, Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      InVITE is funded by NIAID and is conducted in multiple international sites (approximately 20&#xD;
      sites across 7 countries).&#xD;
&#xD;
      This is a study of adults who receive locally available COVID-19 vaccines through local&#xD;
      vaccination programs. Persons will be enrolled within one day (before or after) of receipt of&#xD;
      a COVID-19 vaccine. The study will enroll participants who receive COVID-19 vaccination at&#xD;
      local clinics and/or study sites.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter study of COVID-19 vaccine immunogenicity and durability, and&#xD;
      breakthrough serious acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in&#xD;
      people who receive a COVID-19 vaccine through their country's national vaccination programs.&#xD;
      Participants will be enrolled upon signing the informed consent within a day of receipt of a&#xD;
      COVID-19 vaccine (before or after). The study team will not be administering the vaccine;&#xD;
      receipt of vaccine will be provided through each country's vaccine program. Blood specimens&#xD;
      will be collected to measure the immune response to the vaccine. Participants may be asked to&#xD;
      contact study staff at any time during the study for evaluation if they develop symptoms&#xD;
      consistent with SARS-CoV-2 infection, at which time they will be counseled about the need for&#xD;
      a medical evaluation that may include collection of an upper airway swab for diagnosis (and&#xD;
      research) and a blood sample for research. Infections will be confirmed by molecular or&#xD;
      antigen (Ag) testing at the time of symptoms, and swabs will be collected and stored for&#xD;
      viral sequencing and analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1. To characterize immunogenicity (by measurement of anti-Spike [S] antibody [Ab]) of available COVID-19 vaccines in the overall study population, in each of the countries and in defined subgroups</measure>
    <time_frame>2 months</time_frame>
    <description>Measured by amount of Anti-S Ab at 2 months after completion of vaccine regimen.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate duration of immunogenicity</measure>
    <time_frame>1 day, 2 months, 10 months</time_frame>
    <description>Measured by Anti-S Ab at different specific timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate immunogenicity in predefined subgroups (by age, body mass index [BMI], comorbidities, HIV, breakthrough infection, or evidence of prior infection with SARS-CoV-2).</measure>
    <time_frame>1 day, 2 months, 10 months</time_frame>
    <description>Measured by levels of Anti-S Ab in predefined subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize virus causing breakthrough infections using viral genomic sequencing.</measure>
    <time_frame>1 day</time_frame>
    <description>Measured from sequencing to characterize SARS-CoV-2 variants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare immunogenicity between different vaccines.</measure>
    <time_frame>2 months</time_frame>
    <description>Measured by Anti-S Ab levels at 2 months post-vaccine regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate infection rates after vaccination.</measure>
    <time_frame>1 day</time_frame>
    <description>Measured by levels of anti-nucleocapsid Ab</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>COVID-19</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, and nasal swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be people who are about to receive or have already received a&#xD;
        Coronavirus disease 2019 (COVID-19) vaccine through the local vaccination program.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  Ability to provide informed consent.&#xD;
&#xD;
          -  Enrollment within one day (before or after) of receipt of COVID-19 vaccine.&#xD;
&#xD;
          -  Willingness to be evaluated (including collection of blood and nasopharyngeal samples)&#xD;
             during the prescribed study visits and/or during acute illness consistent with&#xD;
             SARS-CoV-2 infection during the study period.&#xD;
&#xD;
          -  Willingness to allow storage of biological samples for research testing as outlined in&#xD;
             this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any acute or chronic condition that, in the opinion of the investigator, is a&#xD;
             contraindication to participation in this study; for example, acute febrile illness.&#xD;
&#xD;
          -  Inability to comply with study visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee Ridzon, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irini Sereti, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sally Hunsberger, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Hunsberger, PhD</last_name>
    <phone>240-699-5257</phone>
    <email>sally.hunsberger@nih.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irini Sereti, MD</last_name>
    <phone>301-496-5533</phone>
    <email>isereti@niaid.nih.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute for Biomedical Research/Institut National de Recherche Biomédicale (INRB)</name>
      <address>
        <city>Gombe</city>
        <state>Kinshasa</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI)</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Jakarta - RSU Kabupaten Tangerang</name>
      <address>
        <city>Tangerang</city>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Partnership for Research in Vaccines and Infectious Diseases in Liberia (PREVAIL) - Duport Road Health Center</name>
      <address>
        <city>Monrovia</city>
        <country>Liberia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LaRed Network</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LaRed Network</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LaRed Network</name>
      <address>
        <city>Oaxaca</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>LaRed Network</name>
      <address>
        <city>Tapachula</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sally Hunsberger, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
    <country>Guinea</country>
    <country>Indonesia</country>
    <country>Liberia</country>
    <country>Mali</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 26, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2 Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

